Clinuvel Pharmaceuticals Ltd has released a press release.
Preliminary results from SCENESSE adolescent EPP study
Filed with ASX ·
Watch Clinuvel Pharmaceuticals' latest callClinuvel Pharmaceuticals (ASX:CUV) Q4 2026 Earnings Call · Replay · Aug 27Read the transcript of Clinuvel Pharmaceuticals (ASX:CUV) Q4 2026 Earnings Call6ix hasn’t read this filing yet.
Clinuvel Pharmaceuticals Limited on 6ix
Story so far
Earlier from Clinuvel Pharmaceuticals
- Vitiligo - CUV105 Study Update
- Health Canada validates SCENESSE New Drug Submission
- Chair's letter to Shareholders
- SCENESSE dosage expansion under review by EMA
- CLINUVEL prioritises three strategic programs
Later from Clinuvel Pharmaceuticals
- Half Year Results Announcement
- Clinuvel Introduces Groundbreaking Vitiligo Program at the World’s Biggest Dermatology Meeting, AAD 2025
- Positive preliminary results for PRENUMBRA Instant in stroke
- CLINUVEL renews share buy-back program
- CUV recruits 200 patients in Phase III vitiligo trial CUV105
Follow Clinuvel Pharmaceuticals into a list and get an email when it puts out news.
Follow Clinuvel Pharmaceuticals